Phenotypic spectrum associated with PTCHD1 deletions and truncating mutations includes intellectual disability and autism spectrum disorder.

Studies of genomic copy number variants (CNVs) have identified genes associated with autism spectrum disorder (ASD) and intellectual disability (ID) such as NRXN1, SHANK2, SHANK3 and PTCHD1. Deletions have been reported in PTCHD1 however there has been little information available regarding the clinical presentation of these individuals. Herein we present 23 individuals with PTCHD1 deletions or truncating mutations with detailed phenotypic descriptions. The results suggest that individuals with disruption of the PTCHD1 coding region may have subtle dysmorphic features including a long face, prominent forehead, puffy eyelids and a thin upper lip. They do not have a consistent pattern of associated congenital anomalies or growth abnormalities. They have mild to moderate global developmental delay, variable degrees of ID, and many have prominent behavioral issues. Over 40% of subjects have ASD or ASD-like behaviors. The only consistent neurological findings in our cohort are orofacial hypotonia and mild motor incoordination. Our findings suggest that hemizygous PTCHD1 loss of function causes an X-linked neurodevelopmental disorder with a strong propensity to autistic behaviors. Detailed neuropsychological studies are required to better define the cognitive and behavioral phenotype.

Autism spectrum disorder in the genetics clinic: a review.

Autism spectrum disorders (ASDs) are a heterogeneous group of neurodevelopmental disorders affecting social communication, language and behavior. The underlying cause(s) in a given individual is often elusive, with the exception of clinically recognizable genetic syndromes with readily available molecular diagnosis, such as fragile X syndrome. Clinical geneticists approach patients with ASDs by ruling out known genetic and genomic syndromes, leaving more than 80% of families without a definitive diagnosis and an uncertain risk of recurrence. Advances in microarray technology and next-generation sequencing are revealing rare variants in genes with important roles in synapse formation, function and maintenance. This review will focus on the clinical approach to ASDs, given the current state of knowledge about their complex genetic architecture.

Hemizygous deletions on chromosome 1p21.3 involving the DPYD gene in individuals with autism spectrum disorder.

We describe the identification and clinical presentation of four individuals from three unrelated families with hemizygous deletions involving the DPYD gene at chromosome 1p21.3. DPYD encodes dihydropyrimidine dehydrogenase, which is the initial and rate-limiting enzyme in the catabolism of pyrimidine bases. All four individuals described met diagnostic criteria for autism spectrum disorder with severe speech delay. Patient 1's deletion was originally reported in 2008, and more detailed clinical information is provided. Subsequently, this male individual was found to have a missense mutation in the X-linked PTCHD1 autism susceptibility gene, which may also contribute to the phenotype. Patients 2 and 3 are siblings with a novel deletion encompassing the DPYD gene. In their mother, the genomic region deleted from chromosome 1p21.3 was inserted into chromosome 10. A fourth proband had a novel 10-kb intragenic deletion of exon 6 of the DPYD gene detected on a higher resolution microarray. Our study suggests that hemizygous deletions involving the DPYD locus present with variable phenotypes which can include speech delay and autistic features, and may also be influenced by additional mutations in other genes, issues which need to be considered in genetic counseling.

Conservation of RET proto-oncogene splicing variants and implications for RET isoform function.

The RET proto-oncogene encodes a receptor tyrosine kinase required for development of the kidney and neural crest-derived cell types. Alternative splicing of the 3' exons of human RET results in three protein isoforms with distinct C-termini: RET9, RET51, and RET43. These RET isoforms show differential binding to downstream adapter molecules, suggesting they may have distinct signaling functions. We have characterized Ret 3' sequences in mouse and investigated alternative splicing of this region. We found that the organization of Ret 3' sequences is very similar to human RET. The mouse locus also has alternatively spliced C-terminal coding regions, and the sequences corresponding to RET9 and RET51 are highly conserved in both position and sequence with the human locus. Further, we compared the predicted C-terminal amino acids of RET9 and RET51 in seven vertebrate species, and found that they are well conserved. We have identified sequence encoding a putative ret43 isoform in mouse, however the predicted amino acid sequence showed low homology to human RET43. Our data suggest that RET isoforms are evolutionarily highly conserved over a broad range of species, which may indicate that each isoform has a distinct role in normal RET function.

Dielectric properties of a binary cryoelectrochemical solvent according to a solvatochromic probe.

The application of a solvatochromic dye to determination of the dielectric properties of organic solvent mixtures is described. The dye 2,6-diphenyl-4-(2,4,6-triphenylpyridino)phenolate (Reichardt's dye) features an intramolecular charge transfer band in its visible spectrum with a large associated change in dipole moment between the ground and excited states. The position of the charge transfer band is sensitive to local dielectric environment and so is an indicator of solvation of the dye. Room-temperature spectra of Reichardt's dye in the cryoelectrochemical solvent system 2:1 (v/v) ethyl chloride/butyronitrile and in the neat components are reported and related to the dielectric properties of the mixture. The effective dielectric properties of the mixture scale with the value of the Pekar factor, 1/ε(OP) - 1/ε(S), that is predicted from the mole fraction-weighted (or volume fraction-weighted) sum of the dielectric constants for the pure components, suggesting that strongly selective solvation of the dye by one component of the solvent mixture does not occur. The results are pertinent to a recent study of electrode kinetics in the solvent mixture.

Electrochemical investigations of the interaction of metal chelates with DNA. 3. Electrogenerated chemiluminescent investigation of the interaction of tris(1,10-phenanthroline)ruthenium(II) with DNA.

The electrogenerated chemiluminescence (ECL) that results from the oxidation of tris(1,10-phenanthroline)ruthenium(II), at a gold electrode in the presence of oxalate, was used to investigate the interaction of the Ru(II) chelate with calf thymus DNA. The decrease in ECL emission from the excited state, Ru(phen)3(2+*), in the presence of DNA, is ascribed to binding to binding of the chelate to the DNA strand. An ECL titration of the metal complex with DNA allowed determination of the equilibrium constant (K) and binding-site size (s) for association of Ru(phen)3(2+), under the assumption that only the free metal complex contributes to the observed emission. In 25 mM Na2C2O4, 2 mM phosphate buffer, pH 5, 0.05% Tween-20, 0.05% Triton X-100, regression based on the McGhee/von Hippel model, which accounts for free base pair gaps between binding sites, yielded K = 8.1 (+/- 0.2) x 10(3) M-1 and s = 4 bp.